AVEO Pharmaceuticals (AVEO) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to AVEO Pharmaceuticals (AVEO) Misses Q3 EPS by 6c
March 6, 2015 6:05 AM EST
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the
full year ended December 31, 2014.
At the beginning of 2015, AVEO implemented several important changes
designed to maximize the value of our portfolio of clinical stage
products, said Michael Bailey, president and chief executive officer.
Our approach to realizing this value is to leverage biomarker insights,
including the promising new NRP-1 findings for tivozanib in metastatic
colorectal cancer, and our demonstrated ability to advance our assets
through partnerships. In support of these efforts, we have streamlined
our organization to better... More
March 6, 2015 6:00 AM EST
Results Presented at AACR Tumor Angiogenesis and Vascular
Normalization Conference
AVEO to Host Conference Call Today, March 6, 2015 at 8:00 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
AVEO Oncology (NASDAQ: AVEO) today announced the presentation of final
results, including a predefined biomarker analysis, from the BATON- (Biomarker
Assessment of Tivozanib
in ONcology) CRC study, a randomized Phase
2 clinical trial of modified FOLFOX6 combined with tivozanib or
bevacizumab in metastatic colorectal cancer (CRC). The presentation,
titled... More
